Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis

Highlights • Postmenopausal osteoporosis patients suffer fractures in spite of being on bisphosphonate therapy and with good adherence. • It is unknown whether estradiol and sclerostin circulating levels are associated with inadequate response to bisphosphonate therapy in this population. • Several...

Full description

Saved in:
Bibliographic Details
Published in:Maturitas 2015-12, Vol.82 (4), p.402-410
Main Authors: Morales-Santana, Sonia, Díez-Pérez, Adolfo, Olmos, José M, Nogués, Xavier, Sosa, Manuel, Díaz-Curiel, Manuel, Pérez-Castrillón, José L, Pérez-Cano, Ramón, Torrijos, Antonio, Jodar, Esteban, Rio, Luis Del, Caeiro-Rey, José R, Reyes-García, Rebeca, García-Fontana, Beatriz, González-Macías, Jesús, Muñoz-Torres, Manuel
Format: Article
Language:English
Subjects:
Aged
Bisphosphonates
Bone Density
Bone Density Conservation Agents - therapeutic use
Bone Morphogenetic Proteins - blood
Case-Control Studies
Diphosphonates - therapeutic use
Estradiol - blood
Female
Fracture risk
Genetic Markers
Humans
Inadequate responders
Incidence
Internal Medicine
Middle Aged
Obstetrics and Gynecology
Osteoporosis, Postmenopausal - blood
Osteoporosis, Postmenopausal - drug therapy
Osteoporotic Fractures - epidemiology
Osteoporotic Fractures - prevention & control
Postmenopausal osteoporosis
Postmenopause
Sclerostin
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Postmenopausal osteoporosis patients suffer fractures in spite of being on bisphosphonate therapy and with good adherence. • It is unknown whether estradiol and sclerostin circulating levels are associated with inadequate response to bisphosphonate therapy in this population. • Several reports showed that estrogen affect sclerostin production. We observed a nonlinear, inverted U-shaped relation between estradiol and sclerostin levels. • Our findings suggest that increased expression of sclerostin, accompanied by estrogen deficiency, can influence the response to bisphosphonate therapy.
ISSN:0378-5122
1873-4111
DOI:10.1016/j.maturitas.2015.08.007